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Liver enzymes were repeated and demonstrated a progressive rise
in alkaline phosphatase, aspartate aminotransferase (AST), and
alanine aminotransferase (ALT). (Table 1) Additional laboratory
studies revealed a complete blood count within normal limits,
total bilirubin 1.4 mg/dL (0.2-1.2 mg/dL), direct bilirubin 0.5
mg/dL (0.0-0.4 mg/dL), PT 13.3 seconds (normal 11.1-15.5
seconds) with INR 1.0 (normal 0.80-1.21), and PTT 56 seconds
(normal 19- 39 seconds). The initial work-up for abnormal
liver enzymes revealed the following: hepatitis A IgG/IgM
antibody, hepatitis B PCR, hepatitis C PCR, CMV quantitative
PCR, antinuclear antibody (ANA), antimitochondrial antibody
(AMA), anti-liver kidney microsomal (anti-LKM) antibody
were all within normal limits, and ceruloplasmin was 109 mg/dL
(normal 22 - 58 mg/dL). An ultrasound of the liver and biliary
tree was unremarkable.

A 28 year-old male was referred to the gastroenterology clinic
for evaluation of abnormal liver enzymes. Three months prior to
presentation he was evaluated at a local emergency department
for vomiting and upper abdominal pain. He described pain
as epigastric and worse after eating. He denied fever, chills or
changes in his urine. At that time, the patient was not jaundiced
but reported having a rash. Laboratory testing was remarkable
for elevated liver enzymes (Table 1). The patient was advised to
follow up with his primary care physician. Though his symptoms
resolved without medical therapy, liver enzymes obtained a few
weeks later by his primary physician demonstrated progressive
elevation and he was referred to the gastroenterology (GI) clinic
for further evaluation.
At the time of presentation to the GI clinic, the patient reported
a mild sore throat. He denied any recent sick contacts. The past
medical history was significant for a Staphylococcus aureus
(MRSA) infection 6 months prior for which he was successfully
treated with antibiotics. Around the same time, he reports being
HIV negative. Since the course of antibiotics, he had not taken
any medications, herbal supplements, vitamins, or other over
the counter medications, but drank green tea 2-3 times a week.
There was no family history of liver disease. The patient was a
bisexual male, used alcohol occasionally and denied tobacco use.
He had a distant history of inhaled cocaine use, and had never
used intravenous drugs nor had he ever received a transfusion.

A liver biopsy was entertained, but before proceeding an
additional test was ordered based on the history of rash and
pattern of liver enzyme elevation – a rapid plasma reagin (RPR).
The RPR was reactive with a titer of 1:256. A confirmatory
fluorescent treponemal antibody absorbed (FTA-ABS) was
reactive and the patient was diagnosed with secondary syphilis
with hepatic involvement. Upon diagnosis, the patient reported
being informed of negative test results for both syphilis and
HIV approximately 6 months prior to this presentation. He
was treated with 2.4 million units of benzathine penicillin
G intramuscularly. Given the new diagnosis of a sexually
transmitted disease, repeat HIV testing was also recommended
and was negative. As presented in Table 1, the liver enzymes
improved rapidly following treatment.

On physical examination, the patient was a well-developed,
well-nourished African American male who appeared
comfortable. Vital signs revealed a blood pressure of 137/89 and
pulse of 67. There was no scleral icterus, the mouth and oral
pharynx appeared normal, and there was no palpable lymphadenopathy. Cardiovascular and pulmonary exams were normal.
The abdomen was soft with normal bowel sounds, non-tender,
non-distended, and without hepatosplenomegaly, masses, or
dullness at the flanks. Both the rectal and genital exams were
normal. Skin examination revealed no rashes, jaundice, or
stigmata of liver disease.

Discussion

Syphilis is a complex disease caused by the spirochete
Treponema pallidum. More prevalent in the pre-antibiotic era,
this infectious disease remains a global health issue today. The
disease was the leading cause of neurologic and cardiovascular
disease among the middle-aged population at the turn of the 20th
century.1 Many notable figures have been suspected of having
syphilis including Ivan the Terrible, Napoleon Bonaparte and
Ludwig van Beethoven. In modern times, the number of cases of

Table 1. Liver Enzyme History
Initial Presentation
(time 0)

+ 5 weeks

+ 9 weeks

+10 weeks

Post-Treatment
(2 weeks)

Post-Treatment
(8 weeks)

Alkaline Phosphatase
(29-92 IU/L)

448

1198

1412

1538

439

132

AST (7-42 IU/L)

272

184

165

306

63

41

ALT (1-45 IU/L)

502

304

242

328

78

45

Arrow indicates start of treatment
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primary and secondary syphilis in the United States decreased
during the 1990s and reached its nadir in 2000 since reporting
began in 1941. However, recently the reported number of cases
of early syphilis (primary and secondary) in the United States
has begun to rise as demonstrated by an increase from 5,979
reported cases in 2000 to 11,181 in 2007.2 This infection appears
to particularly afflict men who have sex with men (MSM), with
this group accounting for 65% of the cases as of 2007.3
Untreated, this disease can span decades and cause a wide
array of manifestations affecting multiple organ systems, which
accounts for it being referred to as the “great imitator.” It can
present acutely, or chronically with a more indolent course.
Syphilis is typically acquired by contact with a skin or mucosal
lesion, often sexually, but may also be acquired congenitally. The
natural history of syphilis has been well described and progresses
through distinct phases. Primary syphilis is characterized by a
chancre, a painless indurated lesion occurring at the primary
site of inoculation. The time from inoculation to presentation
of chancre is inversely proportional to inoculating dose, but
typically this incubation period ranges from 10 to 90 days.4
About 25 percent of individuals with untreated primary infection
will develop secondary syphilis, usually occurring 2 to 8 weeks
after appearance of the chancre.5 Secondary (disseminated)
syphilis most commonly involves the skin as a maculopapular
rash involving palms and soles; however, the disease can
involve almost any organ in the body. Mucocutaneous, renal,
neurologic, gastrointestinal, hepatic and pulmonary manifestations have all been reported.6 Constitutional symptoms such
as fever, headache, malaise, anorexia, sore throat, myalgias, and
weight loss may be present. As the manifestations of secondary
syphilis subside, the disease enters a latent period. Latent
syphilis is characterized by positive serologies with no clinical
signs of infection. Relapse of secondary syphilis can occur as
late as 4 years after initial contact, but 75 percent of relapses
occur within the first year. Cellular immunity is thought to play
a role in the pathogenesis. About one third of untreated patients
with latent syphilis develop tertiary syphilis in as early as one
year, or as late as 25 to 30 years, after initial infection.5 Tertiary
syphilis presents with symptomatic involvement of the central
nervous system (CNS), cardiovascular system, or the skin and
subcutaneous tissues. CNS findings can include meningitis,
general paresis, tabes dorsalis (disease of the posterior columns
of spinal cord) and meningovascular disease. Cardiovascular
disease mainly involves the aortic root, which can lead to aortic
insufficiency. Gummatous syphilis can manifest as ulceration
on the skin or a mass lesion involving the viscera.5
Secondary syphilis, the diagnosis in the patient we have
described, is an uncommon and often overlooked cause
of hepatitis. 7 Unfamiliarity with the wide-ranging clinical
presentations of secondary syphilis may delay or prevent
diagnosis, unfortunate given the availability of highly effective

therapy. Approximately 10% of patients with secondary syphilis
may have liver enzyme abnormalities, but clinically apparent
hepatitis is rare.8 The exact mechanism of disease is unknown
but it has been proposed that direct portal venous inoculation
and immune complex-mediated processes may be involved. 9
As in this case, the pattern of liver enzymes found in syphilitic
hepatitis often has a cholestatic pattern with a disproportionate
elevation of alkaline phosphatase and a less prominent elevation
of aminotransferases. One study of HIV-positive patients with
syphilitic hepatitis showed alkaline phosphatase levels ranging
from 234 to 1870 IU/L at time of diagnosis.10 Hyperbilirubinemia
is not commonly seen.11 Liver biopsy, generally unnecessary
if the diagnosis is entertained and appropriate serologic
testing obtained, demonstrates nonspecific findings including
periportal lymphocytic inﬁltration with focal necrosis around
central veins, portal areas, and lobules. Trepenomes or
granulomatous changes are seen in nearly half of cases.12
T. pallidum, the organism responsible for syphilis, cannot be
cultured in a laboratory. The quickest and the most direct
method of diagnosing primary and secondary syphilis is by
direct visualization of exudate from the primary lesion using
darkfield microscopy. This requires specialized equipment
and experienced technicians to recognize the spirochetes. The
use of this method is limited to clinics dedicated to diagnosing
and treating sexually transmitted diseases. An alternative
method of direct spirochete visualization is the use of direct
fluorescent antibody testing (DFA-TP). DFA-TP utilizes
flourescence microscopy to examine specimens incubated with
fluorescein-labeled anti-T. pallidum globulin. This method also
requires specialized equipment and trained personnel which is
not widely availability, and therefore most patients suspected
of having syphilis are diagnosed using an indirect method serologic testing.13 There are two types of serologic tests. The
first type is the nontreponemal test, which detect antibodies
against cardiolipin-cholesterol-lecithin antigens. Examples
are the Venereal Disease Research Laboratory (VDRL) and
the Rapid Plasma Reagin (RPR). Positive results are reported
as an antibody titer, and these tests are relatively inexpensive
and easy to perform. The second type of serologic testing is
specific treponemal tests, which detect antibodies against
the treponemes and/or its cellular components. Examples of
these tests are fluorescent treponemal antibody absorption
(FTA-ABS) test, microhemagglutination test (MHA-TP) and
Treponema pallidum particle aggluitnation assay (TPPA). These
are qualitative tests reported as either reactive or non-reactive.
Nontreponemal tests are 78% to 86% sensitive in primary
syphilis and close to 100% sensitive in secondary syphilis.14 Both
nontreponemal and treponemal-specific tests can be falsely
positive for many reasons including acute febrile illnesses and
immunizations. These test abnormalities typically disappear
within 6 months. Chronic illnesses are also implicated as causes
of false positive testing including autoimmune disorders like
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systemic lupus erythematosus, intravenous drug use, chronic
liver disease and HIV infection. False negative results can also
occur, and this may be seen in as many as 20-30% of patients
presenting with a chancre of primary syphilis.15
Direct visualization techniques, i.e., darkfield microscopy and
DFA-TP, are the only definitive methods of diagnosing early
syphilis. Current recommendations state that use of only one
serologic test is not adequate for making a diagnosis.16 For
screening purposes in those who are asymptomatic, a VDRL
test should be done and those with positive results should
get confirmation using a treponemal test. Nontreponemal
antibody titer is an indicator of disease activity and thus can
be used to monitor disease progress. A four-fold change in
titer is considered clinically significant.16 Contrary to this, a
person with reactive treponeme-specific tests will have lifelong
reactivity even if they are not symptomatic and therefore such
testing is not appropriate for monitoring disease. Any person
with positive treponemal tests should have a nontreponemal
test with titer to assess the status of disease.16
The recommended treatment regimen for adults with primary,
secondary and early latent syphilis is benzathine penicillin G
2.4 million units IM in a single dose. Late latent syphilis or
latent syphilis of unknown duration requires three doses of 2.4
million units IM each at one-week intervals.16 As seen in our
patient, following treatment the liver enzymes rapidly improve
and this response to treatment offers further confirmation
of the diagnosis. All patients should be reevaluated 6 and 12
months after treatment. A four-fold reduction in titer of the
nontreponemal antibody test (e.g., from 1:16 to 1:4) is considered
evidence of an appropriate response. The two nontreponemal
tests (VDRL and RPR) cannot be compared directly, so serial
monitoring should be performed with the same test. Those
without symptomatic improvement or a sustained four-fold
reduction in nontreponemal titers should be retreated.
Early detection is imperative in a disease like syphilis where
definitive treatment is available and devastating permanent
consequences are possible if left untreated. Although a case of
fulminant hepatic failure requiring liver transplant secondary to
syphilitic hepatitis has been reported, patients should not have
any sequelae of chronic liver disease if appropriate treatment is
given.12 Because of the varied presentation of secondary syphilis,
the diagnosis of syphilitic hepatitis should be entertained
in anyone presenting with vague constitutional symptoms
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and acute liver dysfunction with a cholestatic pattern when
obstruction, primary disorders such as primary biliary cirrhosis
and sclerosing cholangitis, and environmental exposure have
been excluded. Clinicians need to have a heightened index of
suspicion for this disease in patients at higher risk for syphilis
including those with HIV infection and MSM in order to
eliminate the need for unnecessary and invasive testing and
offer patients rapid resolution of their disease.

References
1.

Tramont EC. The impact of syphilis on humankind. Infect Dis Clin North Am
2004;18:101-10.

2.

Centers for Disease Control and Prevention. Sexually transmitted diseases
surveillance, 2007. Atlanta, GA: U.S Department of Health and Human Services,
2008(Accessed August 2, 2009 at http://www.cdc.gov/std/stats07/toc.htm.).

3.

Centers for Disease Control and Prevention. Sexually transmitted disease
surveillance 2007 supplement, syphilis surveillance report. Atlanta, GA: U.S.
Department of Health and Human Services, Centers for Disease Control
and Prevention, 2009 (Accessed August 2, 2009 at http://www.cdc.gov/std/
Syphilis2007/.).

4.

Greenstone CL, Saint S, Moseley RH. A hand-carried diagnosis. N Engl J Med
2007;356:2407-11.

5.

Tramont EC. Treponema pallidum (Syphilis). In: Mandell, Bennett, Dolin, ed.
Principles and practice of infectious diseases. 6th ed. Orlando, FL: Churchill
Livingstone, 2005.

6.

McPhee SJ. Secondary Syphilis: Uncommon manifestations a common disease.
West J Med 1984;140:35-42.

7.

Mandach C, Coca C, Capro-Sampara F, et al. A forgotten aetiology of acute
hepatitis in immunocompetent patient: syphilitic infection. J Intern Med
2006;259:214-5.

8.

Almoujahed MO, Johnson LB, Khatib R. Syphilitic hepatitis presenting with fever
and inguinal lymphadenopathy without rash: a case report. Infectious Diseases in
Clinical Practice 2002;11:286-7.

9.

Ridruejo E, Mordoh H, F., Avagnina A, Mando OO. Severe cholestatic hepatitis
as the first symptom of secondary syphilis. Dig Dis Sci 2004;49:1401-4.

10. Mullick CJ, Liappis AP, Benator DA, Roberts AD, Parenti DM, Simon GL.
Syphilitic hepatitis in HIV-infected patients: a report of 7 cases and review of the
literature. Clin Infect Dis 2004;39:e100-5.
11. Young MF, Sanowski RG. Syphilitic hepatitis. J Clin Gastroenterol 1992;15:175-6.
12. Lo JO, Harrison RA, Hunter AJ. Syphilitic hepatitis resulting in fulminant
hepatic failure requiring liver transplantation. J Infect 2007;54:e115-7.
13. Larsen SA, Steiner BM, Rudolph AH. Laboratory Diagnosis and Interpretation of
Tests for Syphilis. Clin Microbiol Rev 1995;8:1-21.
14. Golden MR, Marra CM, Holmes KK. Update on syphilis: resurgence of an old
problem. J Am Med Assoc 2003;290:1510-4.
15. Hart G. Syphilis tests in diagnostic and therapeutic decision making. Ann Intern
Med 1986;104:368-76.
16. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines,
2006. MMWR Morb Mortal Wkly Rep 2006;55:22-30.

